| irritable bowel syndrome with constipation
Ibsrela vs Trulance
Side-by-side clinical, coverage, and cost comparison for irritable bowel syndrome with constipation.Deep comparison between: Ibsrela vs Trulance with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrulance has a higher rate of injection site reactions vs Ibsrela based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trulance but not Ibsrela, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ibsrela
Trulance
At A Glance
Oral
Twice daily
NHE3 inhibitor
Oral
Daily
GC-C agonist
Indications
- irritable bowel syndrome with constipation
- Chronic idiopathic constipation
- irritable bowel syndrome with constipation
Dosing
irritable bowel syndrome with constipation 50 mg orally twice daily, taken immediately prior to breakfast or the first meal of the day and immediately prior to dinner.
Chronic idiopathic constipation, irritable bowel syndrome with constipation 3 mg taken orally once daily, with or without food.
Contraindications
- Age less than 6 years due to risk of serious dehydration
- Known or suspected mechanical gastrointestinal obstruction
- Age less than 6 years (risk of serious dehydration)
- Known or suspected mechanical gastrointestinal obstruction
Adverse Reactions
Most common (>=2%) diarrhea, abdominal distension, flatulence, dizziness
Serious severe diarrhea
Postmarketing pruritis, rash, urticaria
Most common (>=2%) Diarrhea
Postmarketing Skin itching, hives, rash, vomiting
Pharmacology
Tenapanor is a locally acting inhibitor of NHE3 (sodium/hydrogen exchanger 3) expressed on the apical surface of the small intestine and colon; by blocking sodium absorption, it increases luminal water secretion, accelerates intestinal transit, and reduces visceral hypersensitivity-mediated abdominal pain.
Plecanatide is a GC-C agonist and structural analog of human uroguanylin that acts locally on the luminal surface of the intestinal epithelium; activation of GC-C increases intracellular and extracellular cGMP, stimulating chloride and bicarbonate secretion via the CFTR ion channel to increase intestinal fluid and accelerate transit.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ibsrela
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
Trulance
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (7/12) · Qty limit (9/12)
UnitedHealthcare
Ibsrela
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Trulance
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Ibsrela
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Trulance
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Ibsrela Commercial Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Trulance.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IbsrelaView full Ibsrela profile
TrulanceView full Trulance profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.